Work

A new therapeutic target for osteoporosis: Arcyriaflavin A as a CDK4 inhibitor suppressing osteoclastogenesis

Year: 2025

Type: conference-paper

Abstract: Objectives and questions: Macrophage polarization influences osteoclast differentiation, a process regulated by the JAK-STAT3 pathway. CDK4 inhibits this pathway by preventing STAT3 activation. We identified Arcyriaflavin A (ArcyA), an indole-based compound, as a natural CDK4 inhibitor and investigated [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/25dkou195

Authors: Zhu, Mengbo, Xu, Mingwei, Bertheloot, Damien, Brom, Victoria, Sieberath, Alexander, Salber, Jochen, Wang, Shaowei, Schildberg, Frank Alexander

Institutions: University Hospital Bonn, Second Hospital of Shanxi Medical University, Ruhr University Bochum, Universitätsklinikum Knappschaftskrankenhaus Bochum

Language: English

Topic: Bone Metabolism and Diseases

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7103198133

FWCI:

Cites:

Cited by:

Related to: